Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas

Gastric Cancer Clinical Trial

Official title:

A Phase II Study of Cisplatin and Irinotecan Induction Chemotherapy, Followed by ZD 1839 (IRESSA) in Adult Patients With Surgically Unresectable and/or Metastatic Esophageal or Gastric Carcinomas

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00215995
• Other study ID #: MCC-13426
• Secondary ID: USFIRB#101525
• Status: Completed
• Phase: Phase 2
• First received: September 19, 2005
• Last updated: January 12, 2012
• Start date: July 2003
• Est. completion date: May 2007

Study information

• Verified date: May 2007
• Source: H. Lee Moffitt Cancer Center and Research Institute
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study is for patients with esophageal, esophagogastric, or gastric cancer that has spread to other parts of the body. The purpose of this study is to test the safety and effectiveness of a new experimental drug called ZD 1839 following initial therapy with two other chemotherapy drugs, called Irinotecan (CPT-11) and Cisplatin.

Description:

This is an open-label, non-randomized, multicenter Phase II study designed to evaluate tumor response rates in patients with surgically unresectable and/or metastatic esophageal, esophagogastric, and gastric adenocarcinoma or squamous carcinoma. Study schema is as follows. Patients will receive Irinotecan and Cisplatin on days 1 and 8 every 21 days for a maximum of 6 cycles of therapy. This is then followed by ZD 1839 (Iressa), which is an oral pill taken once daily. During the Iressa phase, patients will be evaluated every 6 weeks. This includes labs, CT scans and physical examination. The exploratory objective of the study is to examine the correlation between epidermal growth factor receptor (EGFR) expression and radiographic response to treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: May 2007
• Est. primary completion date: May 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologic confirmation of esophageal carcinoma (squamous or adenocarcinoma) or gastric adenocarcinoma.

• Surgically unresectable disease and/or metastatic disease.

• No prior chemotherapy therapy.

• Life expectancy > 12 weeks.

• Patients must have the ability to take and retain oral medications.

• Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 (Karnofsky Performance Status [KPS] =50%).

• Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria and computerized tomographic scan performed within 28 days prior to registration.

• Organ system function assessed within 7 days prior to registration and within the following parameters:

• Absolute neutrophil count =1500/mL;

• Platelet count =100,000/mL;

• Hemoglobin level =10.0 gm/dL;

• Serum creatinine =1.5 x IULN (Institutional Upper Limits of Normal); OR Measured creatinine clearance =60 mL/min;

• AST (SGOT) or ALT (SGPT) = 2.5 x IULN (unless the liver is involved by tumor, in which case it must be =5.0 x IULN);

• Total bilirubin =1.5 x IULN.

• Understanding of the subject of the potential and unknown teratogenic risk, as well as their willingness to practice birth control. Should a pregnancy occur while a subject, either father or mother, is receiving study medication, the subject should inform the doctor immediately.

• Aged 18 years or older

• Provision of written informed consent

• For patients with locally advanced disease, subjects must be evaluated by a radiation oncologist prior to study entry, and judged that radiation therapy is not indicated in the subjects therapy.

Exclusion Criteria:

• Prior treatment with EGFR-inhibiting agents, chemotherapy, or radiotherapy for esophagogastric carcinomas.

• Patients must not be receiving any other investigational agents. Use of erythropoietin is allowable. Secondary prophylaxis with granulocyte colony stimulating factor (G-CSF) (Filgrastim) is allowable. The use of granulocyte-macrophage colony stimulating factor (GM-CSF) (Sargramostim) is not allowed on this protocol.

• Uncontrolled brain metastases.

• Patients must not have uncontrolled intercurrent illness at the time of registration including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina, pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• Patients must not have current New York Heart Association Class III or IV heart disease.

• Known human immunodeficiency virus (HIV) infection.

• Pregnant or breast-feeding women.

• Patients who have had prior malignancies, except non-melanoma skin cancer (basal or squamous cell carcinoma) are not eligible for this study; unless greater than 5 years has passed since the event.

• Known severe hypersensitivity to ZD 1839 or any of the excipients of this product.

• Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, or St. John's Wort.

• Treatment with a non-approved or investigational drug within 30 days before Day 1 of trial treatment.

• Incomplete healing from previous oncologic or other major surgery.

• Serum creatinine level greater than Common Toxicity Criteria (CTC) grade 2.

• Any evidence of clinically active interstitial lung disease. Subjects with chronic stable radiographic changes who are asymptomatic need not be excluded.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Esophageal Cancer
• Esophageal Neoplasms
• Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• Cisplatin
As outlined in Detailed Description
• Irinotecan
As outlined in Detailed Description
• ZD 1839
As outlined in Detailed Description

Locations

Country	Name	City	State
Puerto Rico	Ponce School of Medicine	Ponce
Puerto Rico	University of Puetro Rico Cancer Center	San Juan
United States	H. Lee Moffitt Cancer Center & Research Institute	Tampa	Florida

Sponsors (2)

Lead Sponsor	Collaborator
H. Lee Moffitt Cancer Center and Research Institute	AstraZeneca

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Desired Response	Response rate	48 Months	No
Secondary	Duration of Participants' Desired Response	Response duration in months	48 Months	No
Secondary	Participants' Time to Disease Progression	Time to progression in months	48 Months	No
Secondary	Number of Participants With Overall Survival	Overall survival from first participant On Treatment to last participant Off Study	48 Months	No

External Links

•   Moffiitt Cancer Center Clinical Trials website